Immuno-Oncology Pipeline

ImmuneXcite currently has discovery programs across a range of tumor targets.

The company’s proprietary mAbXcite product engine provides:

  • A transformative approach to treating cancer
  • Ability to treat a wide range of solid and liquid tumors
  • Does not compete with checkpoint inhibitors, which are being explored as potential combination therapies to further enhance mAbXcite’s overall effectiveness
  • A simple targeted product that may not require chronic administration
  • Straightforward development and manufacturing